tetano
Editor, Senior Moderator
Sci Transl Med
. 2022 May 5;eabn6868.
doi: 10.1126/scitranslmed.abn6868. Online ahead of print.
Adenovirus type 5 SARS-CoV-2 vaccines delivered orally or intranasally reduced disease severity and transmission in a hamster model
Stephanie N Langel[SUP] #[/SUP][SUP] 1 [/SUP], Susan Johnson[SUP] #[/SUP][SUP] 2 [/SUP], Clarissa I Martinez[SUP] 2 [/SUP], Sarah N Tedjakusuma[SUP] 2 [/SUP], Nadine Peinovich[SUP] 2 [/SUP], Emery G Dora[SUP] 2 [/SUP], Philip J Kuehl[SUP] 3 [/SUP], Hammad Irshad[SUP] 3 [/SUP], Edward G Barrett[SUP] 3 [/SUP], Adam Werts[SUP] 3 [/SUP], Sean N Tucker[SUP] 2 [/SUP]
Affiliations
Abstract
Transmission-blocking strategies that slow the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and protect against coronavirus disease 2019 (COVID-19) are needed. We have developed an orally-delivered Adenovirus type (Ad) 5-vectored SARS-CoV-2 vaccine candidate that expresses the spike protein. Here we demonstrated that hamsters vaccinated by the oral or intranasal route had robust and cross-reactive antibody responses. We then induced a post-vaccination infection by inoculating vaccinated hamsters with SARS-CoV-2. Oral- or intranasal-vaccinated hamsters had decreased viral RNA and infectious virus in the nose and lungs and experienced less lung pathology compared to mock-vaccinated hamsters after SARS-CoV-2 challenge. Naïve hamsters exposed in a unidirectional air flow chamber to mucosally-vaccinated, SARS-CoV-2-infected hamsters also had lower nasal swab viral RNA and exhibited fewer clinical symptoms than control animals, suggesting that the mucosal-route reduced viral transmission. The same platform encoding the SARS-CoV-2 spike and nucleocapsid proteins elicited mucosal cross-reactive SARS-CoV-2-specific IgA responses in a phase 1 clinical trial (NCT04563702). Our data demonstrate that mucosal immunization is a viable strategy to decrease SARS-CoV-2 disease and airborne transmission.
. 2022 May 5;eabn6868.
doi: 10.1126/scitranslmed.abn6868. Online ahead of print.
Adenovirus type 5 SARS-CoV-2 vaccines delivered orally or intranasally reduced disease severity and transmission in a hamster model
Stephanie N Langel[SUP] #[/SUP][SUP] 1 [/SUP], Susan Johnson[SUP] #[/SUP][SUP] 2 [/SUP], Clarissa I Martinez[SUP] 2 [/SUP], Sarah N Tedjakusuma[SUP] 2 [/SUP], Nadine Peinovich[SUP] 2 [/SUP], Emery G Dora[SUP] 2 [/SUP], Philip J Kuehl[SUP] 3 [/SUP], Hammad Irshad[SUP] 3 [/SUP], Edward G Barrett[SUP] 3 [/SUP], Adam Werts[SUP] 3 [/SUP], Sean N Tucker[SUP] 2 [/SUP]
Affiliations
- PMID: 35511920
- DOI: 10.1126/scitranslmed.abn6868
Abstract
Transmission-blocking strategies that slow the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and protect against coronavirus disease 2019 (COVID-19) are needed. We have developed an orally-delivered Adenovirus type (Ad) 5-vectored SARS-CoV-2 vaccine candidate that expresses the spike protein. Here we demonstrated that hamsters vaccinated by the oral or intranasal route had robust and cross-reactive antibody responses. We then induced a post-vaccination infection by inoculating vaccinated hamsters with SARS-CoV-2. Oral- or intranasal-vaccinated hamsters had decreased viral RNA and infectious virus in the nose and lungs and experienced less lung pathology compared to mock-vaccinated hamsters after SARS-CoV-2 challenge. Naïve hamsters exposed in a unidirectional air flow chamber to mucosally-vaccinated, SARS-CoV-2-infected hamsters also had lower nasal swab viral RNA and exhibited fewer clinical symptoms than control animals, suggesting that the mucosal-route reduced viral transmission. The same platform encoding the SARS-CoV-2 spike and nucleocapsid proteins elicited mucosal cross-reactive SARS-CoV-2-specific IgA responses in a phase 1 clinical trial (NCT04563702). Our data demonstrate that mucosal immunization is a viable strategy to decrease SARS-CoV-2 disease and airborne transmission.